Next Article in Journal
Impact of the First and Second Lockdown for COVID-19 Pandemic on Preterm Birth, Low Birth Weight, Stillbirth, Mode of Labor, and of Delivery in Lombardy, Italy
Next Article in Special Issue
The Relationship between Gastroesophageal Reflux Disease and Chronic Kidney Disease
Previous Article in Journal
Diastole/Body Mass Index Ratio Can Predict Post-Thoracoscopic Surgery Metastasis in Stage I Lung Adenocarcinoma
Previous Article in Special Issue
IgG4-Related Oesophageal Disease with Cytomegalovirus Infection: A Case Report
 
 
Correction published on 31 July 2024, see J. Pers. Med. 2024, 14(8), 819.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Nomogram for Predicting Recurrence-Free Survival of Primary Localized Gastrointestinal Stromal Tumor

1
Department of Gastrointestinal Surgery, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
2
Department of Internal Medicine, Chongqing Key Laboratory of Translation Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing 400030, China
3
Department of Pharmacy, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
*
Authors to whom correspondence should be addressed.
J. Pers. Med. 2023, 13(3), 498; https://doi.org/10.3390/jpm13030498
Submission received: 12 February 2023 / Revised: 2 March 2023 / Accepted: 8 March 2023 / Published: 10 March 2023 / Corrected: 31 July 2024
(This article belongs to the Special Issue Clinical Diagnosis and Treatment of Gastrointestinal Diseases)

Abstract

Purpose: This study aimed to establish a new nomogram that predicts recurrence-free survival (RFS) after a complete surgical resection of primary localized gastrointestinal stromal tumors (GISTs); it also aimed to evaluate the discrimination, calibration, and clinical utility of the decision-making nomogram. Methods: The clinicopathological data of patients with primary localized GISTs at the First Affiliated Hospital of Chongqing Medical University from January 2000 to June 2022 were retrospectively analyzed. The clinicopathological data were randomly split into two sets (7:3 ratio) for training and validation. Suitable variables for the construction of a nomogram for the 1-, 3-, and 5-year RFS were selected using univariate and multivariate Cox regression analyses. Receiver operating characteristic (ROC) analysis and a concordance index (C-index) were used to quantify the discrimination of the nomogram and were compared with four commonly used prognostic scoring systems: Memorial Sloan Kettering Cancer Center prognostic nomogram, National Institutes of Health–Fletcher staging system, Chen’s prognostic nomogram, and Air Forces Institute of Pathology risk criteria–Miettinen staging system. The calibration and clinical utility for the decision-making nomogram were validated using calibration curves and decision curves, respectively. Results: In total, 641 patients were screened and analyzed in this retrospective, observational study. RFS was significantly related to tumor size, mitotic count, gender, DOG-1, and adjuvant therapy with imatinib according to the results of the multivariate and univariate Cox analyses. The nomogram was constructed using the above variables (all p < 0.05) for the 1-, 3-, and 5-year RFS. In the training set, the 1-, 3-, and 5-year ROC and C-index values of the nomogram were 0.868, 0.838, 0.816, and 0.830, respectively. For internal validation, we performed model fitting on the validation set, and the 1-, 3-, and 5-year ROC and C-indices were 0.977, 0.845, 0.869, and 0.849, respectively. Among the five GIST prognostic scoring systems, our nomogram had almost all the largest area under these decision curves and had a good calibration capability. Conclusions: The newly constructed nomogram based on tumor size, gender, mitotic count, DOG-1, and adjuvant treatment with imatinib exhibited an excellent performance and may serve as a prognostic scoring system to support therapeutic decision-making and individualized treatment for GISTs in China.
Keywords: recurrence-free survival; gastrointestinal stromal tumor; nomogram; individualized treatment; prediction recurrence-free survival; gastrointestinal stromal tumor; nomogram; individualized treatment; prediction

Share and Cite

MDPI and ACS Style

Ran, P.; Tan, T.; Zhou, H.; Li, J.; Yang, H.; Li, J.; Zhang, J. Nomogram for Predicting Recurrence-Free Survival of Primary Localized Gastrointestinal Stromal Tumor. J. Pers. Med. 2023, 13, 498. https://doi.org/10.3390/jpm13030498

AMA Style

Ran P, Tan T, Zhou H, Li J, Yang H, Li J, Zhang J. Nomogram for Predicting Recurrence-Free Survival of Primary Localized Gastrointestinal Stromal Tumor. Journal of Personalized Medicine. 2023; 13(3):498. https://doi.org/10.3390/jpm13030498

Chicago/Turabian Style

Ran, Pan, Tao Tan, Hui Zhou, Jinjin Li, Hao Yang, Juan Li, and Jun Zhang. 2023. "Nomogram for Predicting Recurrence-Free Survival of Primary Localized Gastrointestinal Stromal Tumor" Journal of Personalized Medicine 13, no. 3: 498. https://doi.org/10.3390/jpm13030498

APA Style

Ran, P., Tan, T., Zhou, H., Li, J., Yang, H., Li, J., & Zhang, J. (2023). Nomogram for Predicting Recurrence-Free Survival of Primary Localized Gastrointestinal Stromal Tumor. Journal of Personalized Medicine, 13(3), 498. https://doi.org/10.3390/jpm13030498

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop